Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination

Highlights • HBsAg in combination with MPL/QS-21 Adjuvant Systems was highly immunogenic. • CD4+ T-cell, memory B-cell and antibody responses persisted for at least 4 years. • Vaccine adjuvant systems offer potential for challenging diseases or populations.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2015-02, Vol.33 (8), p.1084-1091
Hauptverfasser:	Leroux-Roels, Geert, Van Belle, Pascale, Vandepapeliere, Pierre, Horsmans, Yves, Janssens, Michel, Carletti, Isabelle, Garçon, Nathalie, Wettendorff, Martine, Van Mechelen, Marcelle
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant system Adjuvants Adjuvants, Immunologic Adult Allergy and Immunology B-Lymphocytes - immunology B-Lymphocytes - metabolism Cellular immunity Female Follow-Up Studies Hepatitis Hepatitis B - immunology Hepatitis B - prevention & control Hepatitis B Antibodies - blood Hepatitis B Antibodies - immunology Hepatitis B Surface Antigens - immunology Hepatitis B Vaccines - administration & dosage Hepatitis B Vaccines - adverse effects Hepatitis B Vaccines - immunology Hepatitis B virus HIV Human immunodeficiency virus Humans Immune response Immune system Immunity, Cellular Immunity, Humoral Immunologic Memory Laboratories Lipid A - analogs & derivatives Lipid A - immunology Lymphocyte Count Male MPL Peptides QS-21 Saponins - immunology Studies T-Lymphocyte Subsets - immunology T-Lymphocyte Subsets - metabolism Vaccination Vaccine Vaccines Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • HBsAg in combination with MPL/QS-21 Adjuvant Systems was highly immunogenic. • CD4+ T-cell, memory B-cell and antibody responses persisted for at least 4 years. • Vaccine adjuvant systems offer potential for challenging diseases or populations.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.10.078